HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
LLGL2
LLGL scribble cell polarity complex component 2
Chromosome 17 · 17q25.1
NCBI Gene: 3993Ensembl: ENSG00000073350.14HGNC: HGNC:6629UniProt: A0PJJ0
57PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
regulation of establishment or maintenance of cell polaritycytosolprotein bindingcytoplasmneurodegenerative diseasehepatocellular carcinomabreast canceresophageal squamous cell carcinoma
✦AI Summary

LLGL2 (Lethal giant larvae homolog 2) is a scaffolding protein that regulates epithelial cell polarity and serves context-dependent roles in cancer. In normal physiology, LLGL2 functions as part of a polarity complex involved in spindle orientation and epithelial apical-basal polarity establishment 1. However, LLGL2 exhibits divergent functions across cancer types. In estrogen receptor-positive (ER+) breast cancer, LLGL2 is overexpressed and promotes tumor growth by forming a trimeric complex with the leucine transporter SLC7A5 and YKT6 to enhance leucine uptake under nutrient stress, facilitating endocrine therapy resistance 12. Conversely, in colorectal cancer, LLGL2 functions as a tumor suppressor by stabilizing THBS3 mRNA through interaction with CNOT1, thereby inactivating the PI3K-Akt pathway; MDM2-mediated LLGL2 degradation promotes cancer progression 3. In prostate cancer, LLGL2 knockdown induces autophagy and reverses epithelial-mesenchymal transition by upregulating E-cadherin while suppressing pro-EMT markers 4. LLGL2 shows differential cytoplasmic expression in prostatic ductal adenocarcinoma and may serve as a diagnostic biomarker in latent tuberculosis infection 56. These findings establish LLGL2 as a context-dependent regulator with therapeutic implications across multiple malignancies.

Sources cited
1
LLGL2 overexpression in ER+ breast cancer promotes proliferation under nutrient stress via SLC7A5-mediated leucine uptake and forms complex with SLC7A5 and YKT6
PMID: 30996345
2
LLGL2 acts as tumor suppressor in colorectal cancer by stabilizing THBS3 mRNA via CNOT1 interaction and inactivating PI3K-Akt pathway; MDM2 promotes LLGL2 degradation
PMID: 40619612
3
High LLGL2/SLC7A5 co-expression associates with shorter disease-free and overall survival in ER+ breast cancer patients receiving tamoxifen therapy
PMID: 36192404
4
LLGL2 shows differential cytoplasmic expression in prostatic ductal adenocarcinoma versus acinar adenocarcinoma with potential diagnostic significance
PMID: 37805392
5
LLGL2 identified as upregulated diagnostic biomarker for latent tuberculosis infection with correlation to immune cell infiltration
PMID: 39054612
6
LLGL2 knockdown induces autophagy via Vps34/ATG14L upregulation, reverses epithelial-mesenchymal transition in prostate cancer by increasing E-cadherin
PMID: 38720397
7
LLGL2 DNA hypomethylation associated with estrogen signaling activation in never-smoker lung adenocarcinoma without EGFR/ALK alterations
PMID: 38607364
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.44Moderate
hepatocellular carcinomaOpen Targets
0.08Suggestive
breast cancerOpen Targets
0.08Suggestive
esophageal squamous cell carcinomaOpen Targets
0.07Suggestive
ovarian cancerOpen Targets
0.07Suggestive
neoplasmOpen Targets
0.07Suggestive
benign prostatic hyperplasiaOpen Targets
0.06Suggestive
posterior cortical atrophyOpen Targets
0.05Suggestive
hypertriglyceridemia 2Open Targets
0.04Suggestive
pancreatic triacylglycerol lipase deficiencyOpen Targets
0.03Suggestive
placental insufficiencyOpen Targets
0.03Suggestive
gastric cancerOpen Targets
0.02Suggestive
rotator cuff tearOpen Targets
0.02Suggestive
cancerOpen Targets
0.02Suggestive
adenocarcinomaOpen Targets
0.02Suggestive
endometrial cancerOpen Targets
0.02Suggestive
prostate cancerOpen Targets
0.01Suggestive
Patent ductus arteriosusOpen Targets
0.01Suggestive
type 2 diabetes mellitusOpen Targets
0.01Suggestive
hypertensionOpen Targets
0.01Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
PARD3Protein interaction100%PRKCZProtein interaction100%PRKCIProtein interaction100%DLG1Protein interaction99%DLG2Protein interaction99%DLG3Protein interaction99%
Tissue Expression6 tissues
Liver
100%
Lung
58%
Bone Marrow
20%
Ovary
14%
Brain
7%
Heart
5%
Gene Interaction Network
Click a node to explore
LLGL2PARD3PRKCZPRKCIDLG1DLG2DLG3
PROTEIN STRUCTURE
Preparing viewer…
PDB6N8R · 1.91 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.82LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.68 [0.57–0.82]
RankingsWhere LLGL2 stands among ~20K protein-coding genes
  • #7,980of 20,598
    Most Researched57
  • #6,893of 17,882
    Most Constrained (LOEUF)0.82
Genes detectedLLGL2
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
LLGL2 rescues nutrient stress by promoting leucine uptake in ER
PMID: 30996345
Nature · 2019
1.00
2
Ubiquitination-Dependent LLGL2 Degradation Drives Colorectal Cancer Progression via THBS3 mRNA Stabilization.
PMID: 40619612
Adv Sci (Weinh) · 2025
0.90
3
Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer.
PMID: 36192404
Sci Rep · 2022
0.80
4
[Differential expression of LLGL2 in prostate ductal adenocarcinoma and acinar adenocarcinoma and its significance].
PMID: 37805392
Zhonghua Bing Li Xue Za Zhi · 2023
0.70
5
Identification of
PMID: 39054612
Ann Med · 2024
0.60